Medicare Patients Receiving Chimeric Antigen Receptor T-Cell Therapy for Non-Hodgkin Lymphoma: A Real-World Look at Patient Characteristics, Healthcare Utilization and Costs

Historically, there have been limited curative treatment options for patients (pts) who relapse or have refractory Large B Cell Lymphoma (LBCL). Recently, autologous anti-CD19 chimeric antigen receptor T-Cell (CAR T) therapies were approved for the treatment of pts with relapsed or refractory LBCL after ≥ 2 prior systemic therapies.

Source: Biology of Blood and Marrow Transplantation - January 24, 2020 Category: Hematology Authors: Karl M. Kilgore, Iman Mohammadi, Amy Schroeder, Christie Teigland, Anna G. Purdum, Gunjan L. Shah Tags: 56 Source Type: research